Guselkumab shows significant clinical and endoscopic benefits for adults with moderate to severe Crohn disease, offering a ...

New research in rats indicates that a Mediterranean plant may be an effective treatment for ulcerative colitis, a type of inflammatory bowel disease.

The risk for colectomy among Finnish patients with newly diagnosed ulcerative colitis has decreased in the 21st century, likely due to the use of more advanced treatments.

New research in rats indicates that a Mediterranean plant may be an effective treatment for ulcerative colitis, a type of ...

Tumor necrosis factor-α (TNF-α) is a key cytokine involved in the pathogenesis of ulcerative colitis (UC), a chronic inflammatory bowel disease, and has emerged as a promising therapeutic target.

While research suggests having a higher weight may increase your risk for certain conditions, people can be healthy at every ...

Johnson & Johnson (J&J) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its ...

Janssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for ...

It is estimated that more than 5 million people worldwide suffer from ulcerative colitis, a chronic inflammation of the colon ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...

Despite this, real-world data comparing guselkumab and risankizumab effectiveness and safety are quite limited. In the literature, Ruggiero et al. and Viopulus et al. compared the efficacy and safety ...